ClearPoint Neuro, Inc. CLPT shares soared 8.1% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 26.4% loss over the past four weeks. ClearPoint Neuro scored a strong price increase on investors’ optimism surrounding the company’s impending fourth quarter 2025 financial results, which is slated to release on March 17, 2026. Per the Zacks Consensus Estimate, the company’s revenues are expected to increase 24.8% year over year. Loss per share is pegged at 22 cents for the fourth quarter. This company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -10%. Revenues are expected to be $9.7 million, up 24.8% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For ClearPoint Neuro, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CLPT going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> ClearPoint Neuro is part of the Zacks Medical - Instruments industry. EDAP TMS S.A. EDAP, another stock in the same industry, closed the last trading session 2.8% lower at $4.13. EDAP has returned 6.3% in the past month. EDAP TMS' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.16. Compared to the company's year-ago EPS, this represents a change of -220%. EDAP TMS currently boasts a Zacks Ra...

Factorial, a Spanish startup supplying human resources software to enterprises, is in early discussions to raise new funding that will double its valuation to $2 billion, according to people familiar with the matter. The startup may raise as much as $200 million, one of the people said, requesting anonymity as the information is not public. The size of the round and valuation are not yet finalized, the people said. Factorial declined to comment. The valuation would turn Factorial into one of Spain’s most valuable startups. Formed in 2016, the company offers software that can manage functions such as employee time off, payroll, training and recruitment. It was last valued at $1 billion in 2022. The company said it reached $100 million in annual recurring revenue, a metric used by software startups to demonstrate customer growth, last September. HR software is a fiercely competitive field for startups. The market was turbocharged during the Covid-19 pandemic, when many companies had to manage a remote workforce and found existing tools fell short. The rise of artificial intelligence tools that can take on rote administrative work has also impacted the sector. Two of the biggest startups in the space, Deel and Rippling, are embroiled in a bitter legal battle with Rippling accusing Deel of corporate espionage and Deel filed its own suit against Rippling, alleging defamation. German HR software startup Personio last raised $200 million at a valuation of $8.5 billion in June 2022.

Aureus Greenway Holdings ( AGH ) has signed a definitive merger agreement with Powerus, a U.S. Army Special Operations veteran-founded firm developing autonomous drone systems for high-risk military and commercial environments. Notable investors in the combined company include American Venture Partners, Eric Trump, and Donald Trump Jr., with additional support from U.S. drone manufacturer Unusual Machines ( UMAC ) and a strategic $50 million investment . UMAC shares rose 10% in premarket trading, and AGH was up 5%. “The need for and uses of autonomous technologies, such as those produced by Powerus, are front page news given developments in the Middle East and elsewhere," Matthew J. Saker , interim CEO of AGH, stated. "This business combination is not just a compelling opportunity for AGH stockholders, but one made even more relevant by current geopolitical uncertainties." Under the terms of the agreement, Powerus will merge with and into a newly-formed subsidiary of AGH, with Powerus continuing as the surviving entity and AGH adopting the name “Powerus Corporation.” The combined company expects to be listed on Nasdaq under the ticker “PUSA.” The merger transaction was unanimously approved by the boards of directors of both companies and a majority of each company’s stockholders. More on Aureus Greenway Holdings Inc., Dominari Holdings, etc. Unusual Machines: A Speculative Bet Supported By Solid Fundamentals Unusual Machines: The Growth Story Is Strong (Rating Upgrade) U.S. drone market faces shake-up after FCC ruling, Needham says Seeking Alpha’s Quant Rating on Aureus Greenway Holdings Inc. Financial information for Aureus Greenway Holdings Inc.

The presenter also thanked the doctors and nurses who have been helping his dad, and to those who have sent him messages of support, saying: "In times like these it's so nice to feel the love from people."

Byrna Technologies ( BYRN ) expects Q1 FY2026 revenue of approximately $29.0M ($30.72M consensus), an 11% increase from $26.2 million in Q1 FY2025. First quarter revenue reflects the typical post-holiday seasonal moderation following Byrna’s strong holiday-driven fourth quarter. The quarter ended with approximately $1.1 million in backlog, slightly above typical first-quarter levels due to shipment timing at quarter-end. During the quarter, Byrna continued to generate sales across its multiple distribution channels, including its direct-to-consumer platform and expanding retail footprint, as the Company continues to broaden its omnichannel distribution strategy. Byrna plans to report its full financial results for the fiscal first quarter in April. BYRN -7.5% premarket to $11.08 Source: Press Release More on Byrna Technologies Byrna Technologies Inc. (BYRN) Q4 2025 Earnings Call Transcript Byrna Technologies: A 25% Pullback Creates A Fresh High-Risk, High-Reward Entry Byrna technologies appoints Conn Davis as CEO Byrna anticipates continued margin expansion and 2,000-store footprint growth in 2026 as new products launch Seeking Alpha’s Quant Rating on Byrna Technologies

MP Materials (NYSE: MP) sits at the center of one of the most consequential supply chain shifts in modern American industrial policy. With shares at $58.23, up 138.65% over the past year, the market is pricing in a geopolitical shift that has drawn significant attention: the U.S. has almost no domestic rare earth supply chain, ... The Defense Stock You’ve Never Heard Of: Why MP Materials Is a Buy

Billionaire Aliko Dangote ’s oil refinery said it will prioritize supplying fuel in Nigeria, its home market, as long as it can access local crude. The facility, which can process 650,000 barrels a day of oil, paused local supply pending an announcement of new prices for wholesalers, Chief Executive Officer David Bird said at a briefing in Lagos on Monday. Nigeria is among the few countries on the continent that have refineries. Even though many nations produce several millions of barrels of crude oil a day, they lack processing capacity and must import most of their petroleum products from the Middle East. Iran War Leaves Kenya Tracking Tankers for Mideast Supply Economic Shock Looms as Trump’s Gulf War Escalates: Next Africa Oil at $85 Makes Nigeria a Winner, While Congo Has Most to Lose The US and Israel war on Iran has upended the oil market. Crude surged past $100 a barrel on Monday as more major Middle East producers cut output, including OPEC leader Saudi Arabia, with a standstill of tanker traffic through the vital Strait of Hormuz choking off supplies to the rest of the world. Dangote’s refinery is running at full capacity, Bird said. The Next Africa newsletter runs every weekday. Sign up here for the newsletter, and subscribe to the Next Africa podcast on Apple , Spotify or anywhere you listen .

Andres Barrionuevo Lopez/iStock via Getty Images Investment Overview This is my first time providing coverage of Omada Health ( OMDA ) for Seeking Alpha—the San Francisco, California-headquartered health tech firm completed its Initial Public Offering in May last year (2025), raising ~$150m at ~$19 per share. The company discusses its business as follows in its 2025 annual report/ 10K filing , shared by the company last week, alongside its Q4 and full-year 2025 financial results and business updates: We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for the individuals in our programs, which we call our “members.” Our care is designed to improve their health while delivering value for the employers, health insurance companies (“health plans”), health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of December 31, 2025, we had more than 2,000 customers, over 886,000 total members enrolled in one or more programs, and had supported nearly two million members since launch. We sell our programs to customers that cover the cost for covered individuals, either by contracting with us directly or by arranging access through entities that we call “channel partners,” which resell our programs to their own end customers. An overview of the programs Omada offers, and services it provides is shown in the slide below, taken from a company corporate presentation : Omada Health services overview (presentation) Since late October 2025, when stock traded at ~$27 per share, it has generally been in decline, reaching a low of ~$11 last month; however, in the last few weeks, it has found some upside momentum, presently priced at $14 per share, conferring a market cap valuation of ~$813m. Let's begin our analysis of the company by considering Q4 and full-year 2025 results. Omada: 2025 Earnings Analysis The company provides a fairly comprehensive overview of its Q4 and ful...

Swiss National Bank trimmed its position in shares of Qualcomm Incorporated (NASDAQ:QCOM - Free Report) by 6.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,118,100 shares of the wireless technology company's stock after selling 229,800 shares during the period. Swiss National Bank owned about 0.29% of Qualcomm worth $518,727,000 as of its most recent SEC filing. A number of other institutional investors also recently modified their holdings of QCOM. Russell Investments Group Ltd. grew its position in shares of Qualcomm by 0.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,704,771 shares of the wireless technology company's stock worth $283,245,000 after buying an additional 4,662 shares during the last quarter. Schroder Investment Management Group raised its holdings in shares of Qualcomm by 5.0% during the third quarter. Schroder Investment Management Group now owns 1,649,755 shares of the wireless technology company's stock valued at $272,705,000 after acquiring an additional 78,129 shares in the last quarter. SNS Financial Group LLC raised its holdings in shares of Qualcomm by 1.6% during the third quarter. SNS Financial Group LLC now owns 7,462 shares of the wireless technology company's stock valued at $1,241,000 after acquiring an additional 117 shares in the last quarter. Certified Advisory Corp lifted its stake in Qualcomm by 0.6% in the third quarter. Certified Advisory Corp now owns 10,085 shares of the wireless technology company's stock worth $1,678,000 after acquiring an additional 62 shares during the period. Finally, PFG Advisors boosted its holdings in Qualcomm by 10.6% in the third quarter. PFG Advisors now owns 6,405 shares of the wireless technology company's stock valued at $1,066,000 after acquiring an additional 616 shares in the last quarter. 74.35% of the stock is currently owned by hedge funds and other institutional investors. G...

Swiss National Bank reduced its stake in Advanced Micro Devices, Inc. (NASDAQ:AMD - Free Report) by 5.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,673,875 shares of the semiconductor manufacturer's stock after selling 244,100 shares during the period. Advanced Micro Devices makes up approximately 0.4% of Swiss National Bank's investment portfolio, making the stock its 28th biggest position. Swiss National Bank owned about 0.29% of Advanced Micro Devices worth $756,186,000 as of its most recent SEC filing. Get Advanced Micro Devices alerts: Sign Up Other hedge funds have also recently added to or reduced their stakes in the company. ORG Wealth Partners LLC raised its holdings in Advanced Micro Devices by 39.7% in the 3rd quarter. ORG Wealth Partners LLC now owns 162 shares of the semiconductor manufacturer's stock valued at $26,000 after acquiring an additional 46 shares in the last quarter. Koesten Hirschmann & Crabtree INC. grew its holdings in shares of Advanced Micro Devices by 61.0% during the 3rd quarter. Koesten Hirschmann & Crabtree INC. now owns 161 shares of the semiconductor manufacturer's stock worth $26,000 after purchasing an additional 61 shares in the last quarter. Pinney & Scofield Inc. increased its position in shares of Advanced Micro Devices by 81.0% in the second quarter. Pinney & Scofield Inc. now owns 190 shares of the semiconductor manufacturer's stock worth $27,000 after purchasing an additional 85 shares during the period. Aviso Financial Inc. increased its position in shares of Advanced Micro Devices by 400.0% in the third quarter. Aviso Financial Inc. now owns 200 shares of the semiconductor manufacturer's stock worth $32,000 after purchasing an additional 160 shares during the period. Finally, Evolution Wealth Management Inc. acquired a new position in Advanced Micro Devices in the second quarter valued at about $34,000. Institutional investors ...

Swiss National Bank lowered its position in shares of Micron Technology, Inc. (NASDAQ:MU - Free Report) by 4.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,225,900 shares of the semiconductor manufacturer's stock after selling 157,200 shares during the quarter. Swiss National Bank owned approximately 0.29% of Micron Technology worth $539,758,000 as of its most recent filing with the SEC. Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. REAP Financial Group LLC purchased a new position in shares of Micron Technology during the 3rd quarter worth $25,000. Barnes Dennig Private Wealth Management LLC purchased a new stake in shares of Micron Technology in the third quarter valued at $27,000. Howard Hughes Medical Institute acquired a new position in Micron Technology in the second quarter valued at $30,000. Cullen Frost Bankers Inc. increased its stake in Micron Technology by 79.3% in the third quarter. Cullen Frost Bankers Inc. now owns 199 shares of the semiconductor manufacturer's stock valued at $33,000 after purchasing an additional 88 shares during the last quarter. Finally, WealthCollab LLC lifted its position in Micron Technology by 4,500.0% during the second quarter. WealthCollab LLC now owns 276 shares of the semiconductor manufacturer's stock worth $34,000 after buying an additional 270 shares during the period. 80.84% of the stock is owned by hedge funds and other institutional investors. Get Micron Technology alerts: Sign Up Micron Technology Stock Performance Shares of MU stock opened at $370.30 on Monday. The company has a current ratio of 2.46, a quick ratio of 1.78 and a debt-to-equity ratio of 0.19. The company has a market cap of $416.78 billion, a PE ratio of 35.20 and a beta of 1.50. The company's fifty day simple moving average is $379.98 and its 200-day simple moving average is $263.57. Micron Technology, Inc...

Editas Medicine (EDIT) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 21.79%. A quarter ago, it was expected that this genome editing company would post a loss of $0.86 per share when it actually produced a loss of $0.57, delivering a surprise of 33.72%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Editas , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $12.47 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 181.15%. This compares to year-ago revenues of $11.42 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Editas shares have lost about 45.7% since the beginning of the year versus the S&P 500's decline of -11.3%. What's Next for Editas? While Editas has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions....

Stock Market Today: The Dow Jones index dived 500 points Monday as oil prices surged on the U.S.-Iran conflict. Nvidia stock dropped.

Contemporary Amperex Technology Co. Ltd. shares jumped the most in about six months on Tuesday after the world’s largest maker of electric-vehicle batteries’ earnings beat analyst estimates. The stock rose as much as 9.3% in early trading Tuesday, the biggest gain on an intraday basis since Sept. 15, 2025. Net income climbed 42% in 2025 from a year earlier to 72.2 billion yuan ($10.4 billion), ahead of estimates, the Chinese company said late Monday. Revenue rose 17% as more overseas shipments and a burgeoning energy-storage business helped offset cooling demand from China’s EV market. The results solidify CATL’s position as an anchor of the global green energy transition at a time of growing uncertainty for battery makers. The sharper-than-expected slowdown in EV demand is driving some of the industry’s biggest names toward energy storage systems — a sector that’s booming due to the growing integration of renewable energy into power grids and surging demand from AI data centers. That also highlights the diverging trajectories of CATL and BYD Co. , the world’s biggest EV maker that also produces batteries. The latter’s reliance on the EV market has hammered its bottom line and it’s expected to report its worst quarterly sales decline in five years later this month as intense domestic competition and sluggish car sales in China hurt demand. Read More: CATL’s Results May Widen $120 Billion Market Cap Lead Over BYD The revenue of CATL’s energy storage segment jumped by about 9% from the prior year, while total revenues from the company’s overseas segment rose about 18%. International expansion remains a core pillar of CATL’s growth ambitions, despite the headwinds it faces from geopolitics. The company is doubling down on its licensing model to bypass trade barriers in the US and Europe, attempting to monetize its research and development without the political risk that comes with owning physical assets. In Europe, the ramp up of its multibillion-euro plant in Hungary ...

(RTTNews) - Standex International Corporation (SXI) said on Monday that it has sold its display merchandising business, Federal Industries, to AeriTek Global Holdings LLC, a portfolio company of Mill Point Capital, for around $70 million. This divestiture will support continued simplification of the portfolio and focus on larger businesses and fast-growth end-market opportunities, the company noted. Standex intends to use the proceeds from the sale for organic growth opportunities, inorganic initiatives, and debt repayment. For 2025, Federal Industries reported revenue of approximately $35.7 million. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

两家公司周一表示，ABB机器人业务部门已与英伟达达成合作，以缩小工业机器人在虚拟仿真中的表现与在工厂实际运行中的差距。 总部位于瑞士的ABB将利用英伟达Omniverse仿真数据库，通过融入光照、阴影和材质纹理等细节，让机器人训练环境更加贴近真实场景。 ABB机器人业务总裁马克・塞古拉表示：“这将为企业节省大量时间和资金。” 责任编辑：李肇孚

Universal Health Services ( UHS ) has entered into a definitive agreement to acquire Talkspace ( TALK ) for $5.25 per share. The enterprise value for the transaction is around $835M, which UHS intends to finance with borrowings pursuant to its existing revolving credit facility. The transaction was unanimously approved by the respective boards of directors and is expected to close during the third quarter of 2026. Talkspace ( TALK ) is a virtual behavioral healthcare company, with a network of around 6,000 licensed professionals that serve all 50 states. It generated $229M in revenue and provided more than 1.6M therapy and psychiatry sessions in 2025. Marc Miller , president and CEO of UHS, said, "This acquisition aligns with UHS' core growth objectives by accelerating our outpatient and telehealth behavioral health strategies, diversifying our payor mix and delivering a comprehensive, technology-enabled continuum of care that supports innovative approaches to mental health services." TALK shares jumped +7.7% premarket at $5.13. More on Talkspace, Universal Health Services Universal Health Services, Inc. (UHS) Presents at TD Cowen 46th Annual Health Care Conference Transcript Universal Health Services, Inc. (UHS) Q4 2025 Earnings Call Transcript Talkspace: Time To Shine As Profitability Takes Off Universal Health Services outlines 2026 revenue target of up to $18.8B while accelerating AI and outpatient expansion Universal Health Services Q4 2025 Earnings Preview

Alexander ( ALX ) on Monday said it has agreed to sell its Rego Park I property to Northwell Health for $235.5M, expecting net proceeds of about $202M. The transaction is expected to generate a financial statement gain of about $147M and a tax gain of roughly $145M, with $48M recognized in 2025 and about $97M in 2026. The sale is expected to close by the third quarter of 2026, subject to customary closing conditions. More on Alexander's Alexander's: Fed Tailwinds Drive FFO Growth Bottom 10 small-cap stocks with the lowest dividend safety grade Top performing retail REITs year to date for 2025 Seeking Alpha’s Quant Rating on Alexander's Historical earnings data for Alexander's

Subadra Rajappa, head of research at Societe Generale Americas, says US Treasuries “are not a good flight to quality hedge in this environment.” (Source: Bloomberg)

nito100/iStock Editorial via Getty Images Amazon Pharmacy ( AMZN ) is expanding its offering of weight loss medications on its platform with Eli Lilly’s ( LLY ) Zepbound KwikPen now available for same-day delivery. With a valid prescription, customers can buy Zepbound KwikPen, starting at $299 per month for the 2.5 mg starter dose, and receive the injectable weight loss medication delivered as soon as the same day in nearly 3,000 locations. In addition to Zepbound, Amazon Pharmacy ( AMZN ) also offers access to FDA-approved GLP-1 medications, including Eli Lilly’s ( LLY ) Wegovy pill, Mounjaro, and Novo Nordisk’s ( NVO ) Ozempic. "By expanding access to the Zepbound KwikPen with upfront self-pay pricing, we’re making it easier for customers to get the treatments their doctors prescribe in a simpler way—delivered directly and reliably to their homes," said Amazon Pharmacy’s vice president and general manager, Tanvi Patel. Amazon ( AMZN ) shares were briefly jolted higher on the news but have surrendered gains in sympathy with broader market weakness. More on Amazon Amazon: Berkshire Hathaway Q4 Trimming And Capital Lease Accounting In Focus Amazon: I Bought The Recent Sell-Off Amazon: Not The Best Bang For Your Buck Amazon takes big steps in India with an evolving financial platform Amazon advances grocery delivery options in the key market of Brazil

nito100/iStock Editorial via Getty Images Amazon Pharmacy ( AMZN ) is expanding its offering of weight loss medications on its platform with Eli Lilly’s ( LLY ) Zepbound KwikPen now available for same-day delivery. With a valid prescription, customers can buy Zepbound KwikPen, starting at $299 per month for the 2.5 mg starter dose, and receive the injectable weight loss medication delivered as soon as the same day in nearly 3,000 locations. In addition to Zepbound, Amazon Pharmacy ( AMZN ) also offers access to FDA-approved GLP-1 medications, including Eli Lilly’s ( LLY ) Wegovy pill, Mounjaro, and Novo Nordisk’s ( NVO ) Ozempic. "By expanding access to the Zepbound KwikPen with upfront self-pay pricing, we’re making it easier for customers to get the treatments their doctors prescribe in a simpler way—delivered directly and reliably to their homes," said Amazon Pharmacy’s vice president and general manager, Tanvi Patel. Amazon ( AMZN ) shares were briefly jolted higher on the news but have surrendered gains in sympathy with broader market weakness. More on Amazon Amazon: Berkshire Hathaway Q4 Trimming And Capital Lease Accounting In Focus Amazon: I Bought The Recent Sell-Off Amazon: Not The Best Bang For Your Buck Amazon takes big steps in India with an evolving financial platform Amazon advances grocery delivery options in the key market of Brazil

我們平日發聲，聲帶會由開啟轉為閉合，閉合時呼出的空氣會震動聲帶，達致發聲的效果，但如果聲帶閉合不全，就會很難發聲。 當兩邊聲帶閉合時不夠緊密、有罅隙，呼出來的空氣很多都會漏走，令聲音不夠長，好像發不到聲，而發出的亦會是一些氣聲。聲帶閉合不全其中一個原因是聲帶癱瘓。如果有一邊不懂得動而張開了，即使另一邊閉上時也閉不緊。 耳鼻喉科專科醫生關嘉聰表示：「我們的聲帶動作是靠很多喉嚨內小肌肉來控制，而絕大部分小肌肉，都是靠一條喉反神經去控制。這條神經線很長，它是從腦幹出來，會經過頸、左邊甚至延伸至胸腔，再繞回來，控制聲帶肌肉運作。有些不同的情況，如果影響神經線，可造成聲帶癱瘓，可以是腫瘤，會直接影響神經線。一些手術、併發症傷及神經線，亦有些治療都可以，例如一些電療、頸部的電療。」 50多歲的Kudie，數年前做過頸部淋巴手術，但懷疑手術過程中傷了聲帶，令其中一邊聲帶不會動，自此聲音便變得沙啞。 Kudie說：「起初我沒有為意，因為也很少說話，在休養期間也沒有發覺。我以為自己有氣無力，但慢慢覺得不是，不是有氣無力，而是說話好像用力也說不出聲，數月後已明確覺得有很嚴重的聲沙，用盡力也說不出話。」 後來醫生建議她在聲帶注射物料，讓它豐滿一點，改善發聲、閉合不全的情況，氣聲的情況也可以改善，目前聲音已回復七、八成。 醫生提醒，日常要保護聲帶避免發炎，不要過度用聲、大聲說話等，亦要確保每日飲足夠水，飲食盡量清淡。

Nexperia China announces 12-inch wafer breakthrough as tensions with Dutch HQ persist Reuters

Adeia entered a multi-year IP license agreement with AMD and resolved all outstanding litigation between the companies. Key Highlights: The press release was furnished as Exhibit 99.1 in Adeia’s Form 8-K Regulation FD disclosure on March 9, 2026. The agreement resolves all previously disclosed litigation between Adeia and AMD, allowing both to move forward. Original SEC Filing: Adeia Inc. [ ADEA ] - 8-K - Mar. 09, 2026 Disclaimer

未来我国经济预计将延续稳中有进、提质增效的走势。 2026年3月，第一财经研究院发布的“第一财经首席经济学家信心指数”为50.5，高于上月，连续八个月位于50荣枯线以上。 3月5日公布的政府工作报告将年度经济增长目标设定为4.5%~5%，并强调“在实际工作中努力争取更好结果”，展现了积极进取的目标导向和政策取向。经济学家们认为两会的召开传递出宏观政策更加积极有为的强烈信号，未来我国经济预计将延续稳中有进、提质增效的走势。 3月9日，统计局公布数据显示，受春节因素影响，2月份居民消费价格指数（CPI）同比上涨1.3%，PPI同比下降0.9%，降幅比上月收窄0.5个百分点，均高于本月经济学家们的预期。在本期调研中，首席经济学家们对2月固定资产投资累计增速预测均值为-3.2%，1~2月社会消费品零售总额同比增速预测均值为2.4%，1~2月工业增加值同比增速预测均值为5.3%；他们对1~2月贸易顺差的预测均值为1577亿美元。他们对2月新增贷款预测均值为11286.7亿元、社会融资总量预测均值为2.1万亿元，M2同比增速预测均值为8.8%。同时，他们预计未来一个月存款基准利率以及一年期和五年期LPR利率发生变化的可能性较小。 2026年2月28日，人民币对美元中间价为6.9228，经济学家们对3月底人民币对美元中间价的预测均值为6.9，同时，他们对年底人民币对美元中间价预期均值为6.8。 一、信心指数：3月为50.5 第一财经研究院发布的3月“第一财经首席经济学家信心指数”为50.5，继续位于50荣枯线以上。 工银国际程实认为，从全国两会释放的政策信号看，未来一段时间中国宏观经济仍将延续“稳中求进、提质增效”的总体基调。2026年将经济增长目标设定在4.5%~5%的区间，既体现了在外部环境复杂多变、国内结构转型加快背景下的审慎态度，也为调结构、防风险、促改革预留了政策空间。特别是“十五五”开局之年，政策更加注重从中长期发展目标出发，更强调通过优化结构和提升质量，为实现2035年发展目标打牢基础。整体来看，中国经济仍具备较强韧性，增长动力正在逐步转向创新和内需驱动。 毕马威蔡伟表示，总体来看，2月经济景气回调主要受春节季节性因素主导，“内需修复不均、外需短期承压”的分化特征依然明显，而2026年两会的召开为经济持续回升注入关键政策动力。短期来看，两会明确的1.3万亿元超长期特...

Uncertainty around credit exposure and legal risks could weigh on Jefferies in the near term, according to JPMorgan Analyst Ryan Kenny downgraded the bank to equal weight from overweight. He also lowered his price target to $49 from $78, though that still implies upside of 28% ahead for the stock. Kenny cited elevated uncertainty around credit and legal risks. These recent credit developments include a lawsuit from Western Alliance Bank, alleging $126 million in missed payments, as well as approximately $134 million of reported exposure to failed UK mortgage lender MFS. JEF 1Y mountain JEF 1Y chart "Given that the ongoing fallout from recent credit-related events at JEF may persist in the market for some time, we are adjusting our valuation methodology," Kenny wrote. "We see a wide risk-reward as JEF has already de-rated significantly, down 38% YTD. Core business activity is improving and we expect JEF to gain share in IB." The analyst noted that while Jefferies denies any wrongdoing, the market has expressed concerns about additional potential credit risk alongside any future potential fallout, including legal and reputational risks. However, he remains fundamentally bullish on Jefferies' stock. "These concerns could weigh on JEF's multiple for some time. We continue to expect revenue and earnings improvement at JEF and note that JEF's ongoing messaging is that the current business environment is strong," Kenny said. "We expect core business activity at JEF to accelerate as the capital markets environment improves." Shares of Jefferies have plunged 38% this year and are down 32% over the past 12 months.

As the original On the Road scroll heads to auction, a new exhibition uncovers the private life of the Beat legend Among great literary myths, the one of Jack Kerouac is often reduced to a vibe The open road, a cigarette, a postwar rebel leaning on a beat-up car – a masculine archetype of rebellion and hedonism. Kerouac’s 1957 book On the Road was the bible of the beat generation and chronicles, in startlingly unfiltered prose, his travels across the US with fellow writers Allen Ginsberg , William S Burroughs , and his lifelong muse, the dashing Neal Cassady. The book shifted the course of US literature and captured the imagination of a rapidly changing world. Kerouac was crowned king of the beats, a moniker he later despised. This, at least, is what many students of US literature know. But a new exhibition Running Through Heaven: Visions of Jack Kerouac at New York’s Grolier Club aims to rehumanize the myth, with letters from Kerouac that have never been publicly viewed before. Continue reading...

格隆汇3月9日丨据阿拉伯电视台，卡塔尔防空系统目前正在拦截导弹。

More on FuelCell Energy FuelCell Energy: A Day Late And A Dollar Short - Sell FuelCell Energy, Inc. 2025 Q4 - Results - Earnings Call Presentation FuelCell Energy, Inc. (FCEL) Q4 2025 Earnings Call Transcript Earnings week ahead: ORCL, ADBE, LI, NIO, HPE, ZIM, KSS, and more FuelCell Energy Q1 2026 Earnings Preview

格隆汇3月9日｜土耳其国防部周一表示，北约在东地中海部署的防空系统击落了一枚从伊朗发射并进入土耳其领空的第二枚弹道导弹，并警告称将毫不犹豫采取必要措施。这是过去一周内第二枚针对北约成员国土耳其的伊朗弹道导弹。土耳其国防部在声明中表示，一些弹药碎片落在东南部加济安泰普省，但事件未造成人员伤亡。声明呼吁各方遵守土耳其此前发出的警告。